JP2015506955A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506955A5 JP2015506955A5 JP2014555195A JP2014555195A JP2015506955A5 JP 2015506955 A5 JP2015506955 A5 JP 2015506955A5 JP 2014555195 A JP2014555195 A JP 2014555195A JP 2014555195 A JP2014555195 A JP 2014555195A JP 2015506955 A5 JP2015506955 A5 JP 2015506955A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- patient
- composition according
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261592893P | 2012-01-31 | 2012-01-31 | |
| US61/592,893 | 2012-01-31 | ||
| US201261654733P | 2012-06-01 | 2012-06-01 | |
| US61/654,733 | 2012-06-01 | ||
| PCT/EP2013/051865 WO2013113796A1 (en) | 2012-01-31 | 2013-01-31 | Method of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015506955A JP2015506955A (ja) | 2015-03-05 |
| JP2015506955A5 true JP2015506955A5 (enExample) | 2016-03-24 |
Family
ID=47714037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555195A Pending JP2015506955A (ja) | 2012-01-31 | 2013-01-31 | がんを治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150023953A1 (enExample) |
| EP (2) | EP3045543A3 (enExample) |
| JP (1) | JP2015506955A (enExample) |
| KR (1) | KR20140117644A (enExample) |
| CN (1) | CN104204226A (enExample) |
| AU (1) | AU2013214254B2 (enExample) |
| BR (1) | BR112014019034A8 (enExample) |
| CA (1) | CA2863287A1 (enExample) |
| IN (1) | IN2014DN06127A (enExample) |
| RU (1) | RU2014135224A (enExample) |
| WO (1) | WO2013113796A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109504743A (zh) * | 2017-09-13 | 2019-03-22 | 复旦大学附属华山医院 | 阿帕替尼有效生物标志物vegfr-2基因检测试剂盒 |
| CN115427456A (zh) * | 2020-01-29 | 2022-12-02 | 得克萨斯州大学系统董事会 | 基于喹唑啉的酪氨酸激酶抑制剂在具有nrg1融合的癌症的治疗中的用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5559235A (en) | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
| US5342947A (en) | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| US5871918A (en) | 1996-06-20 | 1999-02-16 | The University Of North Carolina At Chapel Hill | Electrochemical detection of nucleic acid hybridization |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| US5491237A (en) | 1994-05-03 | 1996-02-13 | Glaxo Wellcome Inc. | Intermediates in pharmaceutical camptothecin preparation |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| WO1997040462A2 (en) | 1996-04-19 | 1997-10-30 | Spectra Biomedical, Inc. | Correlating polymorphic forms with multiple phenotypes |
| DE69716916T2 (de) | 1996-07-13 | 2003-07-03 | Glaxo Group Ltd., Greenford | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| AT500848B1 (de) | 1999-06-25 | 2008-01-15 | Genentech Inc | Humanisierte anti-erbb2-antikörper |
| BR0111947A (pt) | 2000-06-30 | 2003-05-06 | Glaxo Group Ltd | Composto, composição farmacêutica, método para o tratamento de um distúrbio em um mamìfero, uso de um composto e processo para preparar, um composto |
| WO2007095038A2 (en) * | 2006-02-09 | 2007-08-23 | Novartis Ag | Mutations and polymorphisms of erbb2 |
| AU2008205457A1 (en) * | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms predictive for dual TKI therapy |
| US20100104583A1 (en) * | 2007-01-18 | 2010-04-29 | University Of Southern California | Gene Polymorphisms in VEGF and VEGF Receptor 2 as Markers for Cancer Therapy |
| EP1980626A1 (en) * | 2007-04-13 | 2008-10-15 | Het Nederlands Kanker Instituut | Involvement of lipid kinase, and signal transduction pathway comprising said lipid kinase, in resistance to HER2-targeting therapy |
| WO2008128233A1 (en) * | 2007-04-15 | 2008-10-23 | University Of Chicago | Methods and compositions concerning the vegfr-2 gene (kinase domain receptor, kdr) |
| BR112012003653A2 (pt) * | 2009-08-21 | 2016-03-22 | Smithkline Beecham Cork Ltd | "método de tratar o câncer." |
| WO2011060380A1 (en) * | 2009-11-14 | 2011-05-19 | The Regents Of The University Of California | Pik3ca mutation status and sash1 expression predicts synergy between lapatinib and an akt inhibitor in her2 positive breast cancer |
-
2013
- 2013-01-31 RU RU2014135224A patent/RU2014135224A/ru not_active Application Discontinuation
- 2013-01-31 BR BR112014019034A patent/BR112014019034A8/pt not_active IP Right Cessation
- 2013-01-31 CA CA2863287A patent/CA2863287A1/en not_active Abandoned
- 2013-01-31 WO PCT/EP2013/051865 patent/WO2013113796A1/en not_active Ceased
- 2013-01-31 CN CN201380017091.3A patent/CN104204226A/zh active Pending
- 2013-01-31 KR KR1020147023977A patent/KR20140117644A/ko not_active Withdrawn
- 2013-01-31 AU AU2013214254A patent/AU2013214254B2/en not_active Ceased
- 2013-01-31 EP EP15196262.8A patent/EP3045543A3/en not_active Withdrawn
- 2013-01-31 EP EP13704029.1A patent/EP2809805A1/en not_active Withdrawn
- 2013-01-31 JP JP2014555195A patent/JP2015506955A/ja active Pending
- 2013-01-31 US US14/375,969 patent/US20150023953A1/en not_active Abandoned
-
2014
- 2014-07-21 IN IN6127DEN2014 patent/IN2014DN06127A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dong et al. | MET-targeted therapies and clinical outcomes: a systematic literature review | |
| Ou et al. | Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib | |
| JP7367910B2 (ja) | がんの処置 | |
| US20120130144A1 (en) | Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor | |
| Mukhopadhyay et al. | RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib | |
| US20140135370A1 (en) | Treating cancer with an hsp90 inhibitory compound | |
| JP2014097929A5 (enExample) | ||
| JP2014533284A5 (enExample) | ||
| RU2009132674A (ru) | Комбинированная терапия с использованием ингибиторов ангиогенеза | |
| JP2014530215A5 (enExample) | ||
| Wang et al. | New strategies in esophageal carcinoma: translational insights from signaling pathways and immune checkpoints | |
| JP2017511377A5 (enExample) | ||
| CA2922684A1 (en) | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases | |
| JP2019511550A5 (enExample) | ||
| Specenier et al. | Recurrent head and neck cancer: current treatment and future prospects | |
| AU2023275617A1 (en) | Lasofoxifene combination treatment of er+ breast cancer that has progressed on a cdk4/6 inhibitor | |
| JP7852103B2 (ja) | 固形腫瘍を治療するためのｋｒａｓｇ１２ｃ阻害剤及びｅｇｆｒ阻害剤を含む方法及び組成物 | |
| MX2013015333A (es) | Anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológgicos. | |
| CA2944255C (en) | New derivatives of cephalosporin for treating cancer | |
| RU2015154985A (ru) | Способы лечения рака | |
| Gounant et al. | Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer | |
| CN119997942A (zh) | 用于治疗癌症的化合物 | |
| ES3032036T3 (en) | Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors | |
| TWI569808B (zh) | 肝細胞腫瘤（ｈｃｃ）之治療 | |
| Schvartsman et al. | An unusual case of central retinal vein occlusion and review of the toxicity profile of regorafenib in GIST patients |